Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487177 | 0.85 | SLC6A2 (0.44) | SLC6A2SLC6A3SLC6A4MAOBCYP19A1 | |
| SCHEMBL6591640 | 0.82 | MAOB (0.53) | KDM4EMAOBEEF2KCYP19A1 | |
| SCHEMBL5709373 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4KDM4ECYP19A1 | |
| SCHEMBL181713 | 0.79 | KDM4E (0.56) | KDM4EMAOBEEF2KCYP19A1 | |
| SCHEMBL29657292 | 0.79 | KDM4E (0.56) | KDM4EMAOBEEF2KCYP19A1 | |
| SCHEMBL8873657 | 0.79 | KDM4E (0.56) | KDM4EMAOBEEF2KCYP19A1 | |
| SCHEMBL5902682 | 0.79 | KDM4E (0.43) | SLC6A2SLC6A3SLC6A4KDM4EEEF2K | |
| SCHEMBL6001645 | 0.79 | RAB9A (0.49) | KDM4EEEF2K | |
| SCHEMBL5709329 | 0.78 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL2794212 | 0.78 | KDM4E (0.44) | SLC6A3KDM4EEEF2KCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0076669-A1 | Novel 3-phenyl-1-indanamines, pharmaceutical compositions and methods of preparation | KEFALAS A/S (DK) | 1983-04-13 | — | — | EP | disclosed |